Skip to content
Dosage GuideResearch Reference

TB-4 Fragment (Ac-SDKP) Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for TB-4 Fragment (Ac-SDKP). All information is for educational purposes only.

Quick Answer

In preclinical research, TB-4 Fragment (Ac-SDKP) is typically administered at 50-200 mcg per dose, 1-2 times daily via subcutaneous injection. For cardiac or renal conditions, some studies have explored intravenous administration. Oral bioavailability is poor, so higher doses may be required if taken orally. Human clinical dose-ranging trials are limited.

→ TB-4 Fragment (Ac-SDKP) Benefits→ TB-4 Fragment (Ac-SDKP) Side Effects→ Full TB-4 Fragment (Ac-SDKP) Profile
Table of Contents

Standard Dosage Range

Research dosing range: 50–200 mcg per dose (injection); 200-500 mcg (oral)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Cardiac Fibrosis

50–100 mcg1–2× daily
Duration

4–8 weeks

Subcutaneous or intravenous injection. Studies have explored co-administration with ACE inhibitors.

Renal Fibrosis

50–150 mcg1–2× daily
Duration

4–8 weeks

Subcutaneous or intravenous injection. Monitor renal function during treatment.

Anti-Inflammatory

50–200 mcg1× daily
Duration

4–6 weeks

Subcutaneous injection. May be beneficial for conditions like rheumatoid arthritis or IBD, but clinical evidence is limited.

Hematopoietic Stem Cell Protection (during chemo)

100–200 mcg1× daily
Duration

2–4 weeks

Subcutaneous injection, starting a few days before chemotherapy and continuing during treatment. Monitor blood counts closely.

General Tissue Repair

100 mcg1× daily
Duration

4–6 weeks

Subcutaneous injection. Evidence is primarily preclinical, with limited human data.

Timing & Frequency

For cardiac and renal applications, injections are typically administered in the morning. For stem cell protection, administer prior to chemotherapy. TB-4 Fragment has a short half-life (~4.5 minutes), supporting twice-daily dosing in preclinical models, although once-daily is more practical in research settings.

Cycle Guidance

Most preclinical studies ran 4–8 week protocols. Common research practice uses a 4–8 week cycle followed by a 4-week break. TB-4 Fragment does not appear to suppress endogenous systems, so cycling rationale is primarily precautionary given limited long-term human safety data.

Reconstitution Reference

Quick reference for reconstituting TB-4 Fragment (Ac-SDKP). For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 1 mg per vial
BAC Water Volume1 mL bacteriostatic water for 1 mg/mL concentration
Concentration & DrawAt 1 mg/mL: 100 mcg = 0.1 mL (10 units on a 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution stable up to 14 days refrigerated. Lyophilized powder stable 12-24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard TB-4 Fragment dosage for cardiac fibrosis?
Preclinical research typically uses 50-100 mcg per dose, administered 1-2 times daily via subcutaneous injection. Limited human data exists.
How should I reconstitute TB-4 Fragment?
Reconstitute with bacteriostatic water. Add 1 mL of bacteriostatic water to a 1 mg vial for a concentration of 1 mg/mL. Store refrigerated.
What are the side effects of TB-4 Fragment?
Limited human data is available. Preclinical studies suggest it is well-tolerated. Some users report mild injection site reactions.

Last updated: 2026-02-19